Asieris Pharmaceuticals Co. Ltd. has synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors described as potentially useful for the treatment of bladder cancer.
Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic diseases, cardiovascular, inflammatory and immunological disorders.
Several Gluetacs Therapeutics (Shanghai) Co. Ltd. patents describe molecular glue degraders reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
Previous research has shown that cell division cycle associated 4 (CDCA4) is overexpressed in multiple tumors and is involved in tumor progression. Researchers from Yangtze University and affiliated organizations investigated the role of CDCA4 in bladder cancer.
Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, from Genome & Co. Ltd. Targeting CNTN4 is a new approach that blocks the CNTN4-APP checkpoint interaction on T cells, promoting tumor cell killing, with potential use in cancers that respond poorly to conventional checkpoint inhibitors.
Researchers from the QIMR Berghofer Medical Research Institute in Queensland, Australia and Emory University have shown that a potential new targeted therapy for childhood brain cancer was effective in infiltrating and killing tumor cells in mouse models.
Amid a strengthening offensive against direct-to-consumer drug ads, two senators flagged a Super Bowl ad promoting compounded drugs as part of the company’s attack on the U.S. weight-loss industry that it said was built to keep Americans “sick and stuck.”
Skin Analytics Ltd. received CE mark for its AI-based tool Deep Ensemble for the Recognition of Malignancy (DERM), which can assess images of lesions and detect skin cancer autonomously. The technology has an accuracy rate of 99.8% compared to 98.9% for dermatologists.
Muna Therapeutics ApS has disclosed new potassium voltage-gated channel subfamily A member 3 (KCNA3, Kv1.3) channel blockers reported to be useful for the treatment of cancer, neurodegeneration, cardiovascular, gastrointestinal, immunological, inflammatory, metabolic and renal disorders, among others.
RSS
